A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects.
Given disconcerting low success rates overall in immunotherapy, some leading oncologists are calling for greater scientific rigor in clinical trial design.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination.
Antibody-mediated, immunotherapeutic strategies targeting survivin, a key cancer-related protein, may offer benefit in a variety of cancers.
A USCF team has uncovered molecular insights into meningioma biology that could lead to new, less toxic treatment approaches.
A significant number of patients receiving immune checkpoint inhibitor therapy have developed myocarditis, but the reasons behind it are still unclear.
A team of Finnish researchers has created a deep learning algorithm that appears to help clinicians better predict patient outcomes based on colorectal cancer tissue samples.
A new joint review from ASCO and CAP found insufficient evidence of clinical validity and utility for the use of most ctDNA assays in advanced cancer.
Researchers discovered that estrogen receptor alpha and glucocorticoid receptor are simultaneously expressed in many endometrial cancers, and may be associated with poor prognosis.